Compare PDI & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | PDI | DFTX |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 5.9B |
| IPO Year | 2012 | 2020 |
| Metric | PDI | DFTX |
|---|---|---|
| Price | $14.15 | $33.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 19 |
| Target Price | N/A | ★ $72.33 |
| AVG Volume (30 Days) | ★ 4.1M | 2.0M |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.73 | $14.62 |
| 52 Week High | $19.00 | $49.70 |
| Indicator | PDI | DFTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.27 | 37.40 |
| Support Level | N/A | $32.84 |
| Resistance Level | $14.56 | $38.04 |
| Average True Range (ATR) | 0.21 | 1.55 |
| MACD | 0.04 | -0.23 |
| Stochastic Oscillator | 23.16 | 15.38 |
PIMCO Dynamic Income Fund is a United States-based closed-end management investment company. The fund's investment objective is to seek current income. Its secondary objective is to seek capital appreciation. The fund invests world-wide in a portfolio of debt obligations and other income-producing securities with varying maturities and related derivative instruments. Its investment portfolio includes mortgage-backed securities, investment-grade, and high-yield corporates, corporate and sovereign bonds, other income-producing securities, and related derivative instruments.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.